This inventor holds 1 USPTO granted patent and 1 EPO patent. Top assignee: Genesen Co., Ltd.. Active years: 2019.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2019
Title: Seol Hee Park: Innovator in Immunology
Introduction
Seol Hee Park is a prominent inventor based in Uiwang-si, South Korea. She has made significant contributions to the field of immunology, particularly through her innovative research and development of therapeutic agents.
Latest Patents
Seol Hee Park holds a patent for a Toll-like receptor 4 (TLR4) antagonist. This invention provides a peptide that binds to a TLR4/myeloid differentiation factor 2 (MD2) composite. It inhibits the secretion of interleukin-6 (IL-6), nitrogen monoxide (NO), and reactive oxygen species (ROS). Additionally, it prevents the activation of nuclear factor kappa-light-chain-enhancer of activated B cells (NFκB) and mitogen-activated protein kinases (MAPKs) by inhibiting the TLR4 signaling pathway induced by lipopolysaccharide (LPS). This TLR4 antagonist, including the peptide, is designed for preventing or treating autoimmune diseases and inflammatory diseases. Seol Hee Park has 1 patent to her name.
Career Highlights
Seol Hee Park is currently associated with Genesen Co., Ltd., where she continues her research and development efforts. Her work has been instrumental in advancing therapeutic options for various inflammatory conditions.
Collaborations
She collaborates with notable colleagues, including Sangdun Choi and Tae Hyeon Yoo, who contribute to her research initiatives.
Conclusion
Seol Hee Park's innovative work in developing TLR4 antagonists showcases her commitment to advancing medical science. Her contributions are vital in the ongoing fight against autoimmune and inflammatory diseases.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile